Therapix Biosciences Ltd. (TRPX): Price and Financial Metrics


Therapix Biosciences Ltd. (TRPX)

Today's Latest Price: $0.32 USD

0.30 (-48.90%)

Updated Jul 1 7:51pm

Add TRPX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TRPX Daily Price Range
TRPX 52-Week Price Range

TRPX Stock Price Chart Technical Analysis Charts


TRPX Price/Volume Stats

Current price $0.32 52-week high $4.69
Prev. close $0.62 52-week low $0.25
Day low $0.30 Volume 7,099,200
Day high $0.40 Avg. volume 1,587,268
50-day MA $0.53 Dividend yield N/A
200-day MA $1.06 Market Cap 1.11M

Therapix Biosciences Ltd. (TRPX) Company Bio


Therapix Biosciences Ltd., a specialty pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01 targeted to the ultra-low dose formulation of dronabinol, combined with sublingual and nasal delivery methods, to provide treatment for Mild Cognitive Impairment (MCI). The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is based in Tel Aviv, Israel.


TRPX Latest News Stream


Event/Time News Detail
Loading, please wait...

TRPX Latest Social Stream


Loading social stream, please wait...

View Full TRPX Social Stream

Latest TRPX News From Around the Web

Below are the latest news stories about Therapix Biosciences Ltd that investors may wish to consider to help them evaluate TRPX as an investment opportunity.

Nasdaq to delist Therapix Biosciences; shares down 43%

Nasdaq has informed Therapix Biosciences (TRPX) that it will delist its American Depositary Shares (ADSs) effective tomorrow, July 2, at the open.Yesterday, an Israeli court granted a temporary injunction against the company barring it from making any changes to its share capital or adopting any resolution outside of the normal...

Seeking Alpha | July 1, 2020

Therapix Biosciences Receives Notice of Delisting and Injunction from Israeli Court

Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Injunction from Israeli Court.

Yahoo | July 1, 2020

Therapix Biosciences raises $2.6M in private placement

Therapix Biosciences (TRPX) entered into definitive agreements for the issuance of an aggregate of 5.2M ADSs at a purchase price of $0.50/ADS, and warrants to purchase up to 2.6M ADSs in a private placement.The private placement is expected to result in gross proceeds to Therapix of $2.6M.Net proceeds will be used...

Seeking Alpha | June 29, 2020

Therapix Biosciences raises $2.6M in private placement (NASDAQ:TRPX)

Therapix Biosciences (NASDAQ:TRPX) entered into definitive agreements for the issuance of an aggregate of 5.2M ADSs at a purchase price of $0.50/ADS, and w

Seeking Alpha | June 29, 2020

Therapix Biosciences Raises $2.6 Million in Private Placement

TEL-AVIV, Israel, June 29, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive…

PR Newswire | June 29, 2020

Read More 'TRPX' Stories Here

TRPX Price Returns

1-mo N/A
3-mo -46.94%
6-mo -25.63%
1-year -88.36%
3-year -94.43%
5-year N/A
YTD -71.33%
2019 -65.66%
2018 -39.14%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6051 seconds.